MT 4561
Alternative Names: MT-4561Latest Information Update: 11 Dec 2025
At a glance
- Originator Mitsubishi Tanabe Pharma Corporation
- Developer Tanabe Pharma Corporation
- Class Antineoplastics
- Mechanism of Action BRD4 protein degraders
-
Orphan Drug Status
No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I/II Solid tumours
Most Recent Events
- 01 Dec 2025 Mitsubishi Tanabe Pharma Corporation is now called Tanabe Pharma Corporation
- 22 Oct 2025 Pharmacodynamics and pharmacokinetics data from preclinical trials in Cancer presented at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics 2025 (AACR-NCI-EORTC-2025)
- 30 Apr 2025 Mitsubishi Tanabe Pharma America plans a phase I/II trial for Solid tumours (Late-stage disease) in USA (IV, Infusion) in April 2025 (NCT06943521)